Figure 4. MALAT1 acts as a miR-145 sponge in HK2 cells treated with TGF-β1. (A) Luciferase reporter analysis of the binding between miR-145 and predicted MALAT1 binding sites. (B) Western blot analyses of E-cad, α-SMA and GAPDH expression in HK2 cells transfected with miR-145 mimics, miR-145 inhibitors and their control RNAs. (C and D) CCK8, EdU and cell migration analyses of the viability, proliferation and migration of HK2 cells transfected with miR-145 mimics, miR-145 inhibitors and their control RNAs. (E) qPCR analysis of miR-145 expression in HK2 cells treated with different concentrations of TGF-β1 for 48 h. (F) Western blot analyses of E-cadherin, α-SMA and GAPDH expression in HK2 cells receiving different treatments. (G and H) CCK8, EdU and cell migration analyses of the viability, proliferation and migration of HK2 cells receiving different treatments. GAPDH and U6 were used as controls. *P < 0.05 and **P < 0.01.